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BET inhibitors induce apoptosis 
through a MYC independent 
mechanism and synergise with 
CDK inhibitors to kill osteosarcoma 
cells
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Nicole C Walsh1, 2, Andrew CW Zannettino4, Alistair M Chalk1, 2, Christopher J Burns3, 5 & 
Carl R Walkley1, 2, 6
Osteosarcoma (OS) survival rates have plateaued in part due to a lack of new therapeutic options. 
Here we demonstrate that bromodomain inhibitors (BETi), JQ1, I-BET151, I-BET762, exert potent 
anti-tumour activity against primary and established OS cell lines, mediated by inhibition of 
BRD4. Strikingly, unlike previous observations in long-term established human OS cell lines, the 
antiproliferative activity of JQ1 in primary OS cells was driven by the induction of apoptosis, 
not cell cycle arrest. In further contrast, JQ1 activity in OS was mediated independently of MYC 
downregulation. We identified that JQ1 suppresses the transcription factor FOSL1 by displacement 
of BRD4 from its locus. Loss of FOSL1 phenocopied the antiproliferative effects of JQ1, identifying 
FOSL1 suppression as a potential novel therapeutic approach for OS. As a monotherapy JQ1 
demonstrated significant anti-tumour activity in vivo in an OS graft model. Further, combinatorial 
treatment approaches showed that JQ1 increased the sensitivity of OS cells to doxorubicin and 
induced potent synergistic activity when rationally combined with CDK inhibitors. The greater level 
of activity achieved with the combination of BETi with CDK inhibitors demonstrates the efficacy of 
this combination therapy. Taken together, our studies show that BET inhibitors are a promising new 
therapeutic for OS.
Osteosarcoma (OS) is the most common primary tumour of bone and predominantly affects children 
and adolescents. OS is a heterogeneous disease characterised by atypical osteoblast differentiation and 
production of abnormal osteoid. The most common diagnosis, conventional OS, presents as one of three 
subtypes; osteoblastic, fibroblastic and chondroblastic1. OS has relatively poor patient outcomes particu-
larly in cases presenting with metastases or recurrent disease. Survival rates of 60–70% are achievable 
if patients have localised tumours2. At diagnosis, 25% of initial diagnoses and the majority of patients 
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with recurrent disease have metastasis3. These patients have only ~30% chance of survival2. Contrasting 
with the rapid gains in our understanding of the genetics and cell biology of OS, there have been few 
new treatments introduced in the last three decades. OS is managed with multi-agent chemotherapy 
combined with surgical resection and treatment-related morbidity is common for OS patients4. New 
targeted therapies are urgently required to increase the efficacy of current therapy and reduce the risk of 
long-term therapy-related side effects.
The recurrent genetic lesions in OS are being rapidly uncovered. Most notable are loss of function 
mutations of TP53 in essentially all OS and recurrent mutations in RB, ATRX and DLG25–7. In addition 
to loss of function mutations, amplification and overexpression of MYC and RUNX2 has been linked 
with OS pathogenesis including disease development, chemotherapy resistance, metastatic potential, 
poor response and inferior outcomes8–14. The potential therapeutic utility of targeting MYC in OS has 
been demonstrated in a conditional murine transgenic model, where transient Myc suppression induced 
OS regression15. Increased expression of FOS has been demonstrated in OS16. Mice lacking Fos had an 
osteopetrotic phenotype17, and reciprocally, transgenic mice over-expressing Fos developed OS18 indi-
cating that Fos plays a role in OS pathogenesis. A closely related Fos family member, Fosl1, can res-
cue the bone phenotype of mice lacking Fos indicating a degree of functional redundancy19. Loss- and 
gain-of-function models indicate that Fosl1 acts as a positive regulator of bone formation20,21. Despite 
some redundancy in their roles, only Fos over-expression resulted in OS21. Collectively these studies 
suggest targeted inhibition of MYC, RUNX2, FOS or potentially FOSL1 may represent a novel therapeutic 
approach for OS.
Pharmacological inhibitors of the bromodomain and extra terminal domain (BET) protein family, 
including JQ1, I-BET151 and I-BET762, demonstrate anti-tumour activity in a range of malignancies22–30. 
BET inhibitors (BETi) bind the acetylation recognition pocket of the BET proteins, displacing them from 
chromatin24,26. BRD4 inhibition in particular has been linked with the antiproliferative responses, and 
drives the disruption of oncogenic pathways25–27. In many models, transcriptional suppression of MYC 
is proposed as the primary mechanism of BETi action24,25,28,30. However recent studies demonstrate BETi 
can exert antiproliferative activity through suppression of alternative gene targets27,29. In lung cancer, the 
effects of JQ1 were attributed to inhibition of a network of FOS related genes including FOSL127. As a 
number of the targets of BETi are involved in OS, we tested if BETi showed therapeutic activity against 
OS using a panel of primary OS cell cultures to provide a closer representation of the in vivo tumour.
Here we show that primary OS cell cultures derived from different OS models (murine, human), 
subtypes and primary vs metastatic sites are highly sensitive to BETi. JQ1 antiproliferative effects in 
primary OS derived cells were mediated by rapid induction in apoptosis, yet primary normal osteo-
blasts were protected from the pro-apoptotic effects. We show FOSL1 is a direct target of BRD4 in OS 
and JQ1 suppresses FOSL1 transcription, independent of MYC suppression. Furthermore we provide 
proof-of-principle that JQ1 can enhance standard OS treatments and be combined with CDK inhibitors 
to synergistically kill OS cells. Collectively these findings highlight the therapeutic potential of using 
BETi alone or in combination to treat OS.
Results
OS cells are sensitive to BET inhibition. We treated a panel of genetically diverse human and 
mouse OS cultures, including long term established human OS cell lines and low passage primary cell 
cultures derived from genetically engineered mouse models (GEMM) of OS or human xenograft derived 
material31,32, with the BETi (+)-JQ1 (JQ1). The murine OS cultures were derived from two GEMM of 
human OS that recapitulate the OS fibroblastic and osteoblastic subtypes33,34. Primary tumour derived 
cultures were used to provide a closer representation of the in vivo tumour by limiting potential changes 
related to long term in vitro culture. JQ1 showed antiproliferative activity in all OS cells assessed at 
72 hrs (Fig. 1a). An IC50 concentration in the low nanomolar range (0.047 μM to 0.406 μM) was observed 
across subtypes and species (Fig. 1a). No appreciable differences in IC50 were apparent if cell lines were 
clustered based on species, histological subtype, tumour site (primary vs metastasis), time in culture, 
or basal proliferation rate (Fig. 1a and Supplementary, Fig. 1). To demonstrate specificity, we tested the 
inactive (-)-JQ1 enantiomer that does not inhibit BET bromodomains26. (-)-JQ1 showed no appreciable 
effects on OS cells at concentrations up to 10 μM (Fig. 1b). Additional testing was undertaken with two 
structurally unrelated BETi compounds, I-BET762 and I-BET151. Both compounds demonstrated anti-
proliferative activity in all cultures examined at 72 hrs, with IC50 values predominantly in the nanomolar 
range (Fig. 1c), revealing a potent class effect of BETi on OS cells.
BET inhibition induces apoptosis in primary OS. To identify the cellular mechanism underlying 
the antiproliferative effects of JQ1 in OS we assessed apoptosis and cell cycle status in representative 
primary OS cell cultures (494H, primary mouse fibroblastic; 148I, primary mouse osteoblastic; OS17, 
primary human). JQ1 rapidly induced apoptosis in a dose-responsive manner, evidenced by increased 
levels of cleaved caspase-3 within 24 hrs (Fig.  2a). A significant increase in cells that were Annexin-V 
positive compared to DMSO or (-)-JQ1 treatments in primary OS cell cultures was evident following 
treatment with 1 μM JQ1 for 48 hrs (Fig. 2b). Interestingly, the long established MG63 cell line, despite 
exhibiting an equally pronounced antiproliferative response to JQ1 (Fig. 1a,b), did not undergo apoptosis 
after extended treatment times (48–72 hrs) (Fig. 2c,d). To further investigate the antiproliferative effects, 
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we assessed if JQ1 altered the cell cycle distribution of the cells. The mouse OS cultures (494H, 148I) 
were largely unaffected by treatment with 1 μM JQ1 for 24 hrs (Fig. 2e). Only a marginal decrease in the 
proportion of cells in the S and G2/M phases with a concurrent increase in cells in G0/G1 were observed 
in the human OS17 primary cell culture (Fig. 2e). In contrast, the established MG63 cell line showed an 
accumulation of cells in G0/G1, indicative of a cell cycle arrest.
We next examined the specificity of the anti-OS activity of JQ1 by assessing its effects on normal 
wild-type primary osteoblast cultures. JQ1 treatment for 72 hrs suppressed the proliferation of primary 
osteoblast cultures at an IC50 value of 0.196 μM (Fig. 2f) but did not reduce cell viability at time points 
when apoptosis was induced in JQ1 treated primary OS cultures (24–48 hrs) (Fig. 2g,h). A small decrease 
in the proportion of osteoblast cells in the S and G2/M phases with a concurrent increase in cells in G0/
G1 were observed following 24 hrs of JQ1 treatment (Fig. 2i). Taken together, these data demonstrate that 
JQ1 exerts an antiproliferative activity against primary OS cell cultures by inducing apoptosis rather than 
preventing cell cycle progression. Importantly normal osteoblasts are protected from the pro-apoptotic 
effects of JQ1.
R
el
at
iv
e 
vi
ab
ili
ty
0.01 0.1 1.0 10
Compound (μM)
125
100
75
50
25
0
JQ1
(-)-JQ1
0.01 0.1 1.0 10
Compound (μM)
125
100
75
50
25
0
R
el
at
iv
e 
vi
ab
ili
ty
JQ1
(-)-JQ1
I841H494
R
el
at
iv
e 
vi
ab
ili
ty
0.01 0.1 1.0 10
Compound (μM)
125
100
75
50
25
0
JQ1
(-)-JQ1
0.01 0.1 1.0 10
Compound (μM)
125
100
75
50
25
0
R
el
at
iv
e 
vi
ab
ili
ty
JQ1
(-)-JQ1
36GM71SO
Cell Line IC50 (μM)
148I 0.284 ± 0.035
98Sc 0.115 ± 0.004
89R 0.126 ± 0.003
494L 0.317 ± 0.012
493L 0.050 ± 0.011
148L 0.146 ± 0.017
98L 0.309 ± 0.029
OS17 0.079 ± 0.003
OS9 0.406 ± 0.028
MG63 0.114 ± 0.025
SAOS2 0.217 ± 0.003
U2OS 0.198 ± 0.008
SJSA-1 0.100 ± 0.010
494H 0.122 ± 0.004
493H 0.047 ± 0.009
716H 0.212 ± 0.034
Primary mouse 
Fibroblastic OS
Primary mouse 
Osteoblastic OS
Primary mouse 
Metastatic OS
Primary Human OS
Established Human 
OS cell lines
ba
c
Cell Line I-BET151 
IC50 (μM)
148I
98Sc
89R
494L
493L
148L
98L
OS17
MG63
SAOS2
494H
493H
1.120 ± 0.263
0.459 ± 0.095
0.551 ± 0.023
1.029 ± 0.204
0.231 ± 0.063
0.736 ± 0.086
1.004 ± 0.194
0.571 ± 0.031
0.363 ± 0.033
0.957 ± 0.045
0.324 ± 0.041
0.166 ± 0.047
Primary mouse 
Fibroblastic OS
Primary mouse 
Osteoblastic OS
Primary mouse 
Metastatic OS
Primary Human OS
Established Human 
OS cell lines
I-BET762 
IC50 (μM)
1.845 ± 0.100
0.943 ± 0.243
1.246 ± 0.003
0.628 ± 0.048
1.369 ± 0.279
0.691 ± 0.04
0.278 ± 0.157
Figure 1. BET inhibitors have potent activity against OS cell cultures. (a) IC50 values of OS cell cultures 
treated with JQ1 for 72 hrs. Mean IC50 values ± SEM (n = 2-4). (b) Dose response curves of mouse (494H, 
primary mouse fibroblastic; 148I, primary mouse osteoblastic) and human (OS17, primary human; MG63, 
established human OS cell line) cells treated with JQ1 or (-)-JQ1 for 72 hrs. Mean cell viability ± SEM 
(n = 3-4). (c) IC50 values of cells treated with I-BET151 and I-BET762 for 72 hrs. Mean IC50 values ± SEM 
(n = 2).
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JQ1 exhibits in vivo activity. To investigate the in vivo therapeutic effect of JQ1 we utilised a lucif-
erase tagged subcutaneous graft model. This model paralleled that used by the Pediatric Preclinical 
Testing Program for testing solid tumours32,35. This approach enabled an assessment of the OS intrinsic 
effects of the drug, independent of other cell types such as osteoclasts. The 494H fibroblastic OS culture 
was selected for the model as its JQ1 sensitivity and biological response profile were representative of 
other primary OS cell cultures tested. Mice were injected with OS cells subcutaneously on the dorsal 
hind flank. The tumour was allowed to establish for 1 week prior to mice receiving daily treatments with 
JQ1 (50 mg/kg) or vehicle for 28 days. Mice in both groups demonstrated normal eating and behavioural 
responses, although a lag in weight gain was observed in the JQ1 treatment group compared to vehi-
cle controls (Fig.  3a). There was a striking suppression of proliferation of the OS in JQ1 treated mice 
(Fig. 3b,c). MicroCT analysis at day 28 showed that tumour bone volume was reduced on average by 70% 
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Figure 2. JQ1 induces apoptosis and cell cycle arrest in OS cell cultures. (a) Induction of cleaved caspase 
3 in primary OS cell cultures (494H, primary mouse fibroblastic; 148I, primary mouse osteoblastic; OS17, 
primary human) treated with JQ1 for 24 hrs. (b) Annexin V and 7AAD staining of OS cells treated with 
1 μM JQ1, 1 μM (-)-JQ1 or vehicle (DMSO) for 48 hrs. Plots are representative biological experiments with 
mean number of Annexin V positive cells (n = 3). (c) Cleaved caspase-3 levels in MG63 cells (established 
human OS cell line) treated with JQ1 for 24–48 hrs. (d) Annexin-V/7AAD staining of MG63 cells treated 
with 1 μM JQ1, 1 μM (-)-JQ1 or vehicle (DMSO) for 72 hrs. Plots are representative biological experiments 
with mean number of Annexin-V positive cells (n = 3). (e) Cell cycle profile of OS cells treated for 24 hrs 
with 1 μM JQ1, 1 μM (-)-JQ1 or vehicle (DMSO). Mean cell population percentage ± SEM (n = 4). (f) Dose 
response curves of mouse normal osteoblast cells treated with JQ1 or (-)-JQ1 for 72 hrs. Mean cell viability 
± SEM (n = 3). (g) Cleaved caspase-3 levels in mouse normal osteoblast cells and mouse 494H cells treated 
with JQ1 for 24 hrs. (h) Annexin-V/ 7AAD staining of mouse normal osteoblast cells treated with 1 μM 
JQ1, 1 μM (-)-JQ1 or vehicle (DMSO) for 48 hrs. Plots are representative biological experiments with mean 
number of Annexin-V positive cells (n = 3).
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in JQ1 treated mice (Fig. 3d,e). Tumour masses were on average 50% smaller than vehicle treated mice 
(Fig. 3f). Taken together, these data demonstrate JQ1 has potent anti-OS activity in vivo.
BRD4 knockdown phenocopies BET inhibitors in OS. To assess the contribution of the indi-
vidual BET isoforms, we first determined that Brd2, Brd3 and Brd4 are expressed in mouse OS cells 
(Supplementary Fig. 2a). Similarly, evaluation of microarray data demonstrated that BRD2, BRD3 and 
BRD4 are also expressed in human OS (Supplementary Fig. 2b). We confirmed the expression of BRD2, 
BRD3 and BRD4 in our human and mouse OS cells compared to normal primary osteoblastic cells using 
QPCR. There was increased relative expression of Brd4, Brd2 and Brd3 in murine OS, with the highest 
levels in fibroblastic OS cells compared to normal osteoblastic cells (Fig.  4a and Supplementary Fig. 
3a-b). BRD4 expression was only moderately elevated in human OS cells compared to normal human 
osteoblasts (Fig. 4a and Supplementary Fig. 3c-d).
BRD4 inhibition has been strongly implicated in mediating the activity of JQ125,27. To determine the 
contribution of BRD4 inhibition, we used siRNA against BRD4 in mouse and human OS. Reducing BRD4 
levels (Fig.  4b,c) led to almost a 50% reduction in cell viability in all OS cultures examined (Fig.  4d). 
The anti-proliferative effect in primary OS cells (494H) was due to the induction of apoptosis, evidenced 
by increased levels of cleaved caspase-3 (Fig. 4e). Interestingly, consistent with the response to JQ1, the 
anti-proliferative response to BRD4 loss in MG63 cells was not due to induction of apoptosis (Fig. 4e). 
JQ1 also inhibits the activities of BRD2 and BRD3. siRNA targeting Brd2 and Brd3 in mouse OS cells 
also reduced cell viability to some extent (10-30%) (Supplementary Fig. 4). Therefore BRD4 inhibition is 
the primary mediator of JQ1 activity in OS, but cumulative effects from the inhibition of all three BET 
proteins may contribute.
JQ1 suppresses FOSL1, independent of MYC inhibition. To define the molecular mechanisms of 
BETi activity in OS, we examined genes transcriptionally downregulated by JQ1 in other cancers25,27. We 
focused on MYC, FOSL1 and RUNX2 as potential targets due to their link with OS or osteoblast biology. 
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Figure 3. JQ1 OS activity in vivo. Subcutaneous graft model of OS with 494H fibroblastic OS cells. (a) 
Body weight of mice undergoing treatment with JQ1 (50 mg/kg) or vehicle for 28 days. Mean weight ± SEM 
(n = 12). (b) Representative whole body bioluminescence images of mice at 28 days post treatment with 
JQ1 or vehicle. (c) Bioluminescence imaging assay of tumour burden in mice at day 0, 14, 21 and 28 
post treatment with JQ1 or vehicle. Mean bioluminescence ± SEM (n = 12). Data was log transformed to 
normalise variances before analysis by 3-way ANOVA. (d) Representative microCT reconstructed images 
of tumours in mice treated for 28 days with JQ1 or vehicle. Tumour mass is circled in red. (e) MicroCT 
analysis of tumour bone volume in mice treated for 28 days with JQ1 or vehicle. Mean tumour bone volume 
±SEM (n = 12). * p < 0.05 Mann Whitney ranks test. (f) Tumour weights from mice treated with JQ1 or 
vehicle for 28 days. Data is presented as mean ± SEM (n = 12, from two separate studies). * p < 0.05 calculated 
using Mann Whitney ranks test.
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Firstly, we examined expression changes in OS cultures after JQ1 treatment (500 nM) for 6-24 hrs to iden-
tify early effects of JQ1. In contrast to many reports of MYC suppression in response to JQ123,25,28–30,36, 
we saw either no reduction or, in some instances, slightly increased MYC expression following 6 hrs of 
treatment (Fig. 5a). After 24 hrs, MYC expression had only moderately reduced in 148I cells. Treatment 
with increasing concentrations of JQ1 over 24–48 hrs had negligible effect on MYC protein levels in all 
OS cells examined (Fig.  5b). Hence, under identical conditions to those that induced apoptosis or cell 
cycle arrest, we failed to observe changes in MYC expression suggesting MYC inhibition is not mediating 
the effects of JQ1 in OS.
In contrast to MYC expression, robust reductions in FOSL1 and RUNX2 levels occurred within 6 hrs 
of treatment (Fig. 5a). RUNX2 expression was decreased at 6 hrs, but expression in human OS cells was 
effectively restored after 24 hrs (Fig. 4a). FOSL1 expression levels were significantly repressed within 6 hrs 
of JQ1 treatment, except the MG63 cell line, which only showed a marginal reduction in expression at 
24 hrs (Fig. 5a). Correspondingly, FOSL1 protein levels decreased with JQ1 treatment (Fig. 5b) suggesting 
FOSL1 could be a direct target of BETi.
To determine whether FOSL1 suppression may mediate the response to JQ1, we used siRNA to 
FOSL1. Knockdown of FOSL1 was confirmed (Fig.  5c), and significantly reduced viability up to 45% 
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Figure 5. BET inhibitor activity in OS cells is driven by FOSL1 suppression, independent of MYC 
downregulation. (a) Transcript levels of MYC, FOSL1 and RUNX2 were evaluated by QPCR in OS cells 
treated for 6 hrs or 24 hrs with 500 nM JQ1 or vehicle (DMSO). Mean fold change ± SEM (n = 3). **p < 0.01, 
****p < 0.0001 ANOVA Dunnett multiple comparisons test. (b) Western blot analyses showing MYC and 
FOSL1 protein levels in OS cell cultures treated with JQ1 or vehicle (DMSO) for 24–48 hrs. Protein band 
intensities quantified by ImageJ. (c) FOSL1 transcript levels quantified by QPCR in OS cells transfected 
with siRNAs targeting FOSL1 or a pool of non-targeting siRNAs (Non-T) for 72 hrs. Mean fold change 
± SEM (n = 3). **p < 0.01, ****p < 0.0001 student’s t test. (d) Cell viability in OS cells transfected with 
siRNAs targeting FOSL1 or a pool of non-targeting siRNAs (Non-T) for 72 hrs. Mean fold change ± SEM 
(n = 3). *p < 0.05, ***p < 0.001, ****p < 0.0001 student’s t test. (e) ChIP analysis of BRD4 enrichment at 
FOSL1, RUNX2 and MYC loci in human OS17 cells treated with 1 μM JQ1 or vehicle (DMSO) for 24 hrs. 
Enrichment is normalised to the total input DNA and a background region devoid of genes. Mean ± SEM 
(n = 3). * p < 0.05, ** p < 0.01 students t-test.
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compared to non-targeting siRNAs (Fig. 5d). While the reduction in cell viability was less than observed 
with either BRD4 knockdown or JQ1 treatment, the results support a reduction in FOSL1 mediating the 
effects of JQ1.
The rapid reductions of FOSL1 in response to JQ1 suggested JQ1 may be directly displacing BRD4 
from the FOSL1 locus. We performed chromatin immunoprecipitation to map BRD4 occupancy at the 
FOSL1 locus. BRD4 was localised at the FOSL1 promoter and enhancer regions (Fig. 5e). Following JQ1 
treatment, BRD4 was displaced, most prominently from the promoter. We observed minimal enrichment 
of BRD4 at the RUNX2 promoter region and its occupancy was unchanged in response to JQ1 treatment. 
BRD4 was localised in the coding region of RUNX2, and was displaced following JQ1 treatment (Fig. 5e). 
Enrichment of BRD4 at known sites surrounding the MYC transcription start site in OS cells was weak 
and occupancy was not reduced following JQ1 treatment, consistent with a lack of MYC transcriptional 
response to JQ1 treatment. These results define FOSL1 as a direct target of BRD4 in OS cells.
JQ1 enhances standard OS chemotherapy and synergistically combines with CDK inhibi-
tors. Chemotherapy treatment has improved the outcome of OS patients with localised tumours, yet 
therapy-related morbidity and poor response in patients with metastatic disease still remain significant 
hurdles2,4. We explored whether the addition of JQ1 to standard therapy could increase the efficacy 
of treatment in vitro. We treated a panel of primary OS cells (494H, 148I, OS17) with a dose range of 
doxorubicin combined with low dose JQ1 for 72 hrs and monitored cell proliferation responses. The 
addition of JQ1 was additive to the cytotoxic effects of doxorubicin suggesting JQ1 can chemo-sensitise 
OS cells (Fig. 6a). To further explore the role of BETi in OS response to chemotherapy, siRNA was used 
to deplete BRD4 in primary OS cells (494H, 148I, OS17). Consistent with the effects of combining JQ1 
with doxorubicin, BRD4 depletion significantly increased the antiproliferative response of 494H, 148I 
and OS17 cells to doxorubicin (Fig.  6b), suggesting JQ1 could enhance the sensitivity of OS cells to 
standard therapy.
We further examined the utility of JQ1 in combination therapy approaches. BRD4 recruits the 
P-TEFb complex to promoters including FOSL137, resulting in changes in RNA polymerase II phospho-
rylation and gene expression38. Cyclin dependent kinase 9 (CDK9) forms part of the P-TEFb complex, 
which is potently targeted by the CDK inhibitors, flavopiridol and dinaciclib39. Knockdown of Cdk9 
resulted in a loss of OS cell viability (Fig. 6c,d) and OS cells were highly sensitive to both flavopiridol 
and dinaciclib with IC50 values between 0.2 μM-0.33 μM and 0.007 μM-0.03 μM respectively (Fig.  6e,f 
and Supplementary Fig. 5). Treatment for 24 hrs induced a significant increase in apoptotic Annexin-V 
positive cells (Fig. 6g). We thus hypothesised that a multi-targeting approach of BRD4 activity through 
co-treatment with JQ1 and CDK inhibitors would be highly efficacious in OS.
Combinations of JQ1 with flavopiridol and dinaciclib were tested using effector concentration ranges 
below a 60% inhibition response. Viability was measured and combinatorial synergistic interactions were 
tested using the Bliss-additivity model. Greatly enhanced cell death was achieved when JQ1 was com-
bined with flavopiridol or dinaciclib, reaching up to 50% more than any drug alone (Fig. 6h). Strong syn-
ergism between JQ1/flavopiridol and JQ1/dinaciclib was observed, reaching up to 300% and 80% more 
inhibition than predicted to be additive respectively (Fig.  6i). To further explore the synergy observed 
with co-inhibition of BETi and CDKs, we tested whether knockdown of BRD4 would synergise with 
dinaciclib to kill OS cells. OS cells were transfected with siRNAs to BRD4 or a non-targeting siRNA 
together with 25 nM dinaciclib and cell viability assessed. BRD4 knockdown combined with dinaciclib 
was moderately synergistic (15.64-15.06%), with BRD4 siRNA/dinaciclib treated cells being far greater 
inhibited (44-62%) than non-targeted cells treated with dinaciclib (Fig.  6j). The combination of JQ1 
with dinaciclib resulted in a significant increase in the number of Annexin-V positive cells (Fig.  6k). 
The concurrent inhibition of BRD4 and CDKs is potently synergistic at inducing apoptosis of OS cells.
Discussion
The introduction of chemotherapy to OS treatment protocols resulted in a significant improvement in the 
survival of patients with localised tumours2. However, survival rates have plateaued and improvements 
in survival have been a result of improved delivery of existing treatments rather than from the rational 
application of new targeted agents2,40. In this study we have used a panel of OS cultures to show a potent 
class effect of BETi on OS cells. BETi, predominantly via inhibition of BRD4, had potent antiproliferative 
activity against human and mouse OS irrespective of origin (primary vs metastatic site), subtype, p53 
status and proliferation rate, as well as potent in vivo activity in an OS preclinical model. Despite the 
strong link between BETi activity and MYC suppression in multiple models23,25,28–30,36, we identified JQ1 
anti-OS activity is MYC independent and was instead driven by FOSL1 suppression, similar to effects 
in lung cancer27. In addition, the anti-OS activity of JQ1 was selective, inducing rapid apoptosis in all 
primary OS cells, while normal osteoblasts remained protected from pro-apoptotic effects. Importantly, 
proof-of-principle studies for a BETi combinatorial treatment approach to OS are demonstrated. JQ1 
sensitised OS cells to doxorubicin, a chemotherapeutic agent used in routine OS treatment practices. 
Furthermore, combining JQ1 with CDK inhibitors resulted in synergistic killing of OS, identifying a 
novel rational combinatorial treatment with agents in clinical trials. At least four BETi are currently being 
assessed in Phase I clinical trials. These studies provide a strong rationale for the further testing of BETi 
either alone or in combination clinically in OS.
www.nature.com/scientificreports/
9Scientific RepoRts | 5:10120 | DOi: 10.1038/srep10120
Dinaciclib (μM)
R
el
at
iv
e 
vi
ab
ili
ty
125
100
75
50
25
0
10-5 10-4 10-3 10-2 10-1 100 101
IC50 0.027μM
OS17
Dinaciclib (μM)
R
el
at
iv
e 
vi
ab
ili
ty
125
100
75
50
25
0
10-5 10-4 10-3 10-2 10-1 100 101
IC50 0.03μM
494H
101
Flavopiridol (μM)
R
el
at
iv
e 
vi
ab
ili
ty
125
100
75
50
25
0
10-1 10010-2
IC50 0.216μM
494H
Flavopiridol (μM)
R
el
at
iv
e 
vi
ab
ili
ty
125
100
75
50
25
0
10-1 100 10110-2
OS17
IC50 0.33μM
f
JQ1
OS17
100
80
60
40
20
0
0n
M 25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M2nM
5nM
10nM
25nM
%
 C
ell inhibition
Dinaciclib
494H
100
80
60
40
20
0
0n
M 25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M2nM
5nM
10nM
25nM
%
 C
ell inhibition
JQ1
Dinaciclib
OS17
100
80
60
40
20
0
0n
M 25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M10nM
25nM
50nM
100nM
200nM
%
 C
ell inhibition
JQ1
Flavopiridol
100
80
60
40
20
0
494H
0n
M 25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M10nM
25nM
50nM
100nM
200nM
%
 C
ell inhibition
JQ1
Flavopiridol
40
30
20
10
0
25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M
2nM
5nM
10nM
25nM
JQ1
Dinaciclib
OS17
%
 D
eviation from
 
B
liss A
dditivity
25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M
10nM
25nM
50nM
100nM
200nM
JQ1
Flavopiridol
350
300
250
200
150
100
%
 D
eviation from
B
liss A
dditivity50
0
494Hih
kj
OS17494H
25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M
10nM
25nM
50nM
100nM
200nM
JQ1
Flavopiridol
140
120
100
80
60
40
%
 D
eviation from
B
liss A
dditivity20
0
OS17
25
nM 50
nM 10
0n
M
20
0n
M
40
0n
M
2nM
5nM
10nM
25nM
JQ1
Dinaciclib
100
80
60
40
20
0
%
 D
eviation from
 
B
liss A
dditivity
494H
** *** *125
100
75
50
25
0
N
on
-T
B
rd
4
N
on
-T
B
rd
4
Vehicle Dinaciclib
R
el
at
iv
e 
vi
ab
ili
ty
15
.0
6%
R
el
at
iv
e 
vi
ab
ili
ty
125
100
75
50
25
0
N
on
-T
B
rd
4
N
on
-T
B
rd
4
Vehicle Dinaciclib
16
.6
4%
DMSO 25nM Dinaciclib
100nM JQ1
100nM JQ1 +
25nM Dinaciclib
e
100
75
30
20
10
0
R
el
at
iv
e 
vi
ab
ili
ty
**
**
**
**
*
N
on
-T
N
on
-T
B
rd
4
Doxorubicin
494H
B
rd
4
**
**
N
on
-T
N
on
-T
Doxorubicin
**
**
**
148I
100
75
30
20
10
0
R
el
at
iv
e 
vi
ab
ili
ty
100
75
60
40
20
0
R
el
at
iv
e 
vi
ab
ili
ty
N
on
-T
N
on
-T
B
rd
4
Doxorubicin
**
*
**
*
0.077
OS17
50
0
Doxorubicin dose (nM)
30
0
15
0
10
050302010510
125
100
75
50
25
0
R
el
at
iv
e 
vi
ab
ili
ty
494H
125
100
75
50
25
0
R
el
at
iv
e 
vi
ab
ili
ty
50
0
Doxorubicin dose (nM)
30
0
15
0
10
050302010510
148I
50
0
Doxorubicin dose (nM)
30
0
15
0
10
050302010510
125
100
75
50
25
0
R
el
at
iv
e 
vi
ab
ili
ty
OS17
 R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
**
**
**
**
1.0
0.75
0.5
0.25
0
N
on
-T
49
4H
14
8IC
dk
9 
re
la
tiv
e 
ex
pr
es
si
on
1.0
0.75
0.5
0.25
0
N
on
-T
49
4H
14
8I
**
**
**
**a
b
c d
g
AnnexinV 
7A
A
D
DMSO
1μM Flavopiridol
250nM Flavopiridol
125nM JQ1
250nM JQ1
500nM JQ1
0
10
20
30
40
0
10
20
30
40
50
%
 A
nn
ex
in
 V
 +
ve
DM
SO
25
0n
M
1µ
M
**
AnnexinV 
7A
A
D
%
 A
nn
ex
in
 V
 +
ve
DM
SO
25
nM
 D
ina
c
10
0n
M 
JQ
1
***
10
0n
M 
JQ
1 +
25
nM
 D
ina
c
Figure 6. JQ1 enhances standard OS chemotherapy and synergistically combines with CDK inhibitors. (a) 
Dose response of OS cells treated with doxorubicin in the absence (columns) or presence (lines) of JQ1 for 72 hrs. 
Mean viability ± SEM (n = 3). (b) OS cells transfected with BRD4 siRNA or non-targeting siRNA (Non-T) and 
treated with 100 nM doxorubicin or vehicle (DMSO). Mean fold change cell viability ± SEM, (n = 3). ANOVA 
Tukey multiple comparisons test. (c) Cdk9 mRNA levels in mouse OS cells transfected with Cdk9 siRNA or 
Non-T siRNAs (Non-T) for 72 hrs. Mean fold change expression ± SEM (n = 3). ANOVA Dunnett multiple 
comparisons test. (d) Cell viability in mouse OS cells transfected with Cdk9 siRNA or Non-T siRNAs for 72 hrs. 
Mean fold change viability ± SEM (n = 3). ANOVA Dunnett multiple comparisons test. (e-f) Dose response 
curves of cells treated with flavopiridol or dinaciclib for 48 hrs. Mean ± SEM (n = 2). (g) AnnexinV/7AAD staining 
of OS17 cells treated with flavopiridol or vehicle (DMSO) for 24 hrs. Representative FACS plots; mean ± SEM 
(n = 4 DMSO, n = 3 Flavopiridol treated). ANOVA Dunnett multiple comparisons test. (h) OS cells treated with 
combinations of JQ1 with flavopiridol or dinaciclib for 72 hrs, represented as mean viability inhibition (n = 3). 
(i) Synergy effects of treatment with JQ1 combined with flavopiridol or dinaciclib for 72 hrs. Bliss additivity 
deviations greater than 15% were considered synergistic (red baseline), (n = 3). (j) Cell viability and synergy in 
OS cells transfected with BRD4 siRNA or Non-T siRNA and treated with 25 nM dinaciclib or vehicle (DMSO) 
for 72 hrs. Represented as mean cell viability normalised to vehicle treated Non-T siRNA ± SEM, (n = 3). 
Synergy is represented as mean percent deviation from a predicted additive response (Bliss additivity) (n = 3). 
(k) AnnexinV/7AAD staining of OS17 cells treated with combinations of JQ1 and dinaciclib for 48 hrs. Plots are 
representative biological experiments; results plotted as mean ± SEM Annexin-V positive cells (n = 4 per group). 
ANOVA Dunnett multiple comparisons test. For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Downregulation of MYC has been reported as the mechanism mediating BETi activity in many 
tumour models23–25,28,29. Surprisingly, despite evidence implicating MYC as an oncogenic driver in OS11–
13, MYC was not downregulated by JQ1 in our studies. Instead, we demonstrated FOSL1 is downreg-
ulated and is a significant contributor to the effects of JQ1. Although FOSL1 has been shown to be an 
important regulator of the osteoblastic content of bone by promoting osteoblast differentiation20,21, this 
is the first time FOSL1 has been implicated as a potential therapeutic target in OS. How suppression of 
FOSL1 transcription factor mediates the antiproliferative effects of BETi in OS remains to be determined. 
A closely related family member, FOS, is strongly associated with OS18, and redundancy between FOSL1 
and FOS has been reported19. In lung cancer cells where BETi was shown to suppress FOSL1, a down-
regulated FOS gene signature was detected27. A gene signature common to these transcription factors 
may be important for OS survival.
The loss of viability from FOSL1 knockdown was less than observed with either JQ1 treatment or 
BRD4 knockdown suggesting, not unexpectedly, a multi-factorial action of BETi. Multiple targets are 
likely involved, as previous studies have demonstrated that over-expression of a single putative target 
such as MYC or FOSL1 was insufficient to completely rescue cells from JQ125,41. Indeed we observed 
that JQ1 exposure repressed RUNX2, which has been linked to OS8,9,42. JQ1 has also been shown to 
downregulate anti-apoptotic genes such as BCL224. Loss of BCL-2 has been shown to sensitise OS cells 
to doxorubicin43. An underappreciated aspect of the effects of JQ1 may be the upregulation of genes, 
which may also contribute to BETi activity. Further, JQ1 also inhibits BRD2 and BRD3. Although BRD4 
loss was the most potent in reducing viability, knockdown of Brd2 and Brd3 in mouse OS cells also led 
to decreased survival, suggesting that the antiproliferative effects of JQ1 may not be fully mediated via 
a single target in BRD4.
JQ1 activity in OS cell lines has recently been reported in two independent studies that utilised long 
established OS cell lines41,44. We have confirmed their findings that RUNX2 is suppressed in response 
to JQ1 treatment, however several important differences are evident. Both groups reported that JQ1 
treatment repressed MYC transcription in a subset of OS cell lines41,44. Interestingly, a loss of MYC pro-
tein was not evident or failed to be reported in the long established OS cells in response to JQ141,44, in 
contrast to other tumour models where BETi activity was correlated with significant reductions in MYC 
protein25,29,45. Further, we demonstrated apoptosis was rapidly induced by JQ1 treatment in all primary 
OS cell cultures examined, whereas the prior studies observed apoptosis to be variable and limited in OS 
cell lines41,44. Why such contrasting findings? It perhaps involves the models used for preclinical testing. 
Our studies have deliberately made use of primary OS cultures which provide a closer representation of 
the disease by limiting potential changes from long term in vitro culture. Extended culture conditions 
may result in alternative BRD4 genomic localisation patterns, rendering cell lines differentially suscep-
tible to treatments. The cell type specific effects mediated by JQ1 is proposed to be controlled by cell 
specific asymmetrical super-loading of BRD4 at enhancers of genes involved in cell-fate determination 
and oncogenic drivers23,46. JQ1 treatment leads to a preferential loss of BRD4 at these enhancers and sub-
sequent transcriptional repression23,46. Genome-wide super-enhancer H3K27ac ChIP-Seq analysis could 
distinguish differences that segregated diffuse large B cell lymphoma cell lines from primary samples23. 
Indeed, cell specific BRD4 super-loading of oncogenic drivers in OS cells may explain the protection of 
normal osteoblasts from the pro-apoptotic effects of JQ1 treatment. The protection of normal osteoblasts 
from the pro-apoptotic OS activity of JQ1 provides compelling rational for clinical testing, and warrants 
investigation of OS BRD4 super-enhancers to potentially identify oncogenic susceptibilities.
One function of BRD4 is to recruit P-TEFb to gene promoters where it phosphorylates RNA polymer-
ase II to induce transcriptional elongation38. We tested whether concurrent inhibition of P-TEFb would 
co-operate with JQ1 by further compromising BRD4 function. JQ1 combined with the CDK inhibitors 
dinaciclib or flavopiridol led to synergistic killing of OS in vitro. Synergy was observed with both agents 
suggesting the effects were not compound specific, rather driven by “on target” inhibition of CDKs. The 
molecular basis of the synergistic reaction remains to be determined. Knockdown of BRD4 with dinaci-
clib was able to phenocopy the synergistic effects of the combined pharmacological approach. Dinaciclib 
has been shown to bind and inhibit the activity of BET proteins, albeit to levels significantly less than 
CDKs47. As synergy was still achieved with knockdown of BRD4, the interactions between the drugs is 
not likely driven by direct inhibition of BRD4 by dinaciclib. The more potent effect of JQ1 compared to 
BRD4 knockdown when combined with dinaciclib may reflect contributions from BRD2/3.
The results offer promise for increasing the in vivo efficacy of dinaciclib. Dinaciclib showed in vitro 
activity in multiple cancer cell lines and was well tolerated in pre-clinical testing48,49. We observed that 
primary OS cells are extremely sensitive in vitro to dinaciclib, with IC50 values in the low nanomolar 
range. However in vivo testing of dinaciclib in OS xenografts showed limited activity48. Apart from CLL, 
phase II trials of dinaciclib in multiple malignancies have not yielded encouraging responses 50. Several 
Phase I trials have commenced testing dinaciclib in combination with bortezomib, dexamethasone and 
the AKT inhibitor MK2206. The current findings provide rationale for the testing of dinaciclib and BETi 
combination treatment.
In addition to dinaciclib, JQ1 improved OS cell response to doxorubicin. We demonstrated that JQ1 
and doxorubicin induces additive effects in reducing OS cell viability. Although a synergistic response 
was not achieved, the results indicate the addition of JQ1 could reduce the dose of doxorubicin required 
to achieve the same degree of cell death. Given doxorubicin treatment is associated with severe life 
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threatening side effects4, strategies that can lower the dose of doxorubicin could have significant benefit 
to patients’ morbidity and treatment tolerability.
The ability of BETi to target different oncogenic pathways in different cancers suggests they will have 
wide ranging clinical applications. Our studies provide strong evidence that BET inhibitors represent a 
novel therapeutic strategy to treat OS either as monotherapy or in combination with current or novel 
therapies. We demonstrate that primary tumour derived cell cultures from murine OS models or human 
patient material are highly sensitive to BETi and undergo apoptosis as the primary antiproliferative 
response. This contrasts with work in long established cell cultures, where apoptosis was variable and 
cell cycle arrest and induction of senescence was more prominent. This study emphasises the importance 
of testing novel agents and defining their mechanism of action in models more closely representative of 
the disease as it occurs in patients.
Methods
Cell culture. Cells were maintained in αMEM supplemented with 10% FCS. Human cell lines were 
purchased from ATCC (no authentication performed). Primary human OS cultures were derived from 
tumours from xenograft models31,32 (material generously provided by Dr Peter Houghton, Nationwide 
Children’s Hospital, Ohio; no authentication performed). Normal human osteoblasts were derived from 
bone marrow aspirates from normal healthy individuals51 (no authentication performed). Primary mouse 
OS cultures were derived from tumours from fibroblastic or osteoblastic models of OS33,34 (no authen-
tication performed). Primary osteoblast cells were isolated from C57BL6 mouse collagenase digested 
bones. Osteoblastic cells were purified by flow cytometry (FACSAria, BD Biosciences) as previously 
described52,53, or directly cultured following collagenase digestion. Flow cytometry antibodies are 
described in Supplementary Table S1.
Compounds. (-)-JQ1 (Cayman Chemicals), I-BET151 (ChemieTek), I-BET762 (Millipore), Dinaciclib 
and Flavopiridol (Selleckchem) were purchased. (+)-JQ1 was purchased (Cayman Chemicals) or syn-
thesised as previously described26. Doxorubicin was obtained from St Vincent’s Hospital Pharmacy 
(Melbourne, Australia).
Cell viability and proliferation assays. Cell were seeded 24 h prior to drug treatment at 2500/well 
in 96 well plates. Compounds, diluted in DMSO, were applied (0.01 nM to 10 μM) for 48–72 h and via-
bility quantified using CellTitre-Glo (Promega). Half maximal inhibitory (IC50) values were calculated 
using Prism 6.0e software. Proliferation rate was determined by counting cells on 4-5 consecutive days 
using a BioRad TC10 counter (Hercules, CA, USA).
Synergy calculations. Synergy was calculated using the Bliss-Additivity model54. Experimental 
responses > 15% above the predicted combined response value were considered to indicate synergism54.
Flow Cytometry. Cells were stained with Annexin V-APC (BD Biosciences) (1:20) and 7AAD (5 μg/
ml) and apoptotic cells quantified by FACS (LSRFortessa, BD Biosciences) and analysed using FlowJo 
software (v8.8.7). Cell cycle was determined by staining with propidium iodide (40 mg/ml) and quanti-
fying DNA content by FACS. Cell cycle distributions were analysed using FlowJo software.
RNA extraction and Real-time PCR. QPCR analyses were carried out using primers described in 
Supplementary Table S2 using methods as previously described33,34.
Genome wide expression analyses. RNA-Sequencing was conducted on an Illumina HiSeq 2000 
with 100 bp paired-end reads. Reads were aligned to the mouse genome build mm9/NCBI37 using 
Casava 1.7 and Bowtie v0.12.2 mapping software, normalised using Voom linear modeling55 and tran-
script abundance measured as reads per kilobase of exon per million mapped reads (RPKM)56. Datasets 
are deposited in GEO (accession number GSE58916). Gene expression data from a publicly available 
human OS dataset (accession number GSE3338257) were normalised using R/bioconductor.
siRNA knockdown. Cells were transfected with Dharmacon On-Target Plus siRNA pools (GE 
Healthcare Life Sciences) (20 nM) complexed with DharmaFECT 3 (GE Healthcare Life Sciences) for 
72 h. Cells transfected with a non-targeting On-Target Plus siRNA pool served as controls. Drug treat-
ments commenced 24 to 48 h after siRNA transfection.
Western blotting. Antibodies (BRD4 Bethyl Laboratories; c-MYC [9E10] Abcam ab32; FOSL1 
Abcam ab65051; Cleaved caspase 3 Asp175 [5A1E] Cell Signaling Technologies 9664S; Pan Actin [Ab5] 
Thermo Scientific MS-1295-PO) were used at 1:1000 (FOSL1, Cleaved caspase-3), 1:10,000 (BRD4) and 
1:3000 (pan-actin).
Chromatin Immunoprecipitation. ChIP was carried out on 5 × 106 cells as described previously58. 
Cells were treated with 1 μM JQ1 or 0.1% v/v DMSO for 24 hrs. Cells were fixed with 1% formaldehyde 
diluted in PBS for 10 min at room temperature. Cross-linking was quenched by incubating cells with 
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0.125 M glycine diluted in PBS for 10 min at room temperature. Cells were washed twice in PBS before 
being scraped from plates and pelleted by centrifugation at 400 x g for 5 minutes at room temperature. 
Cell pellets were diluted in sonication buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH8.1) with 
cocktail protease inhibitors (Roche) and the DNA sheared to lengths between 100 and 400 bp using 
a UCD-200 Bioruptor (Diagnenode) on high for a total shearing time of 15 min (90 min of 10 s on 
and 50 s off), maintained at 4 degrees celcius during shearing. Cell debris was cleared by centrifugation 
for 10 min at 13,000 rpm at 4 degrees celcius and supernatants diluted 10-fold in ChIP dilution buffer 
(0.01% SDS, 1.1% Triton X-100, 1.2 mM ETA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCL) with protease 
inhibitors. After removing 20 μl of each sample as an input control, protein-DNA fragments were immu-
noprecipitated with 5 μg BRD4 antibody (Bethyl Laboratories) or control rabbit IgG (Merck Millipore), 
or no antibody overnight at 4 degrees celcius with rotation. Complexes were collected for 1.5 hrs at 4 
degrees celcius with rotation with 60 μl of protein A dynabeads (Invitrogen) that had been pre-blocked 
for 1 hr in 0.5% BSA in TE buffer. Beads were washed one time each with Low Salt buffer (0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 20 m Tris-HCl pH8.1, 150 mM NaCl), High Salt buffer (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 500 mM NaCl) and LiCl buffer (0.25 M LiCl, 1% 
NP40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH8.1), followed by two washes with TE buffer. 
Protein-DNA complexes were eluted from the beads (0.1 M NaHCO3, 1% SDS) with 2 hrs incubation 
at 62 degrees celcius with shaking. Cross-links were reversed overnight at 65 degrees celcius with the 
addition of 0.2 M NaCl. Protein was digested by incubation with 50 μg of proteinase K at 45 degrees 
celcius for 1 hr. DNA was purified by phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma) extraction 
and ethanol precipitation with GlycoBlue (Life Technologies) as a carrier. BRD4 bound and input sam-
ples were analysed by QPCR using primers that amplified regions of the FOSL1, c-MYC and RUNX2 loci 
or a negative control background region (region devoid of genes) (sequences available in Supplementary 
table S2). Relative enrichment was determined by the 2(−deltaCT) method normalizing to input controls 
and background regions.
In vivo studies. All animal experiments were undertaken in accordance with the Australian Code 
of Practice for the Care and Use of Animals for Scientific Purposes (7th edition, 2004 NHMRC; the 
“approved guidelines”) and under experimental protocols approved by the St Vincent’s Hospital 
Melbourne Animal Ethics Committee. 494H mouse fibroblastic OS cells infected with pMMP-LucNeo 
virus were used to generate the model. 25,000 tumour cells (increased to 75,000 in a second independent 
study) resuspended in extracellular matrix (Cultrex PathClear BME Reduced Growth Factor Basement 
Membrane Extract, Trevigen) were implanted sc on the dorsal hind flank of 6–7 week old Balb/c nu/
nu mice. Tumours were allowed to establish for 1 week and were visualised and quantitated by biolu-
minescence imaging before treatment commenced with JQ1 (50 mg/kg) or vehicle (10% DMSO in 10% 
hydroxypropyl beta cyclodextrin) daily by ip injection. Tumour volume was measured using an IVIS 
Spectrum Imaging System (Perkin Elmer). Mice were injected with XenoLight D-luciferin (15 mg/ml) 
(Perkin Elmer) intraperitoneally. Bioluminescence was quantitated using Living Images software (Perkin 
Elmer).
Microcomputed tomography. Tumours were scanned ex vivo using a SkyScan 1076 scanner 
(Bruker). Data acquisition setting were: 18 μm voxel resolution, 0.5 mm aluminum filter, 50 kV voltage, 
200 μA current, 2600 ms exposure, rotation 0.6° across 180°, and frame averaging of 1. Reconstruction 
was performed using NRecon (v.1.6.3.1). Analysis was performed using CT Analyser (CTAn, v.1.12.0.0).
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